Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Nancy C. Andrews reported non-market, bona fide gifts of common stock. On May 12, 2026, she disposed of a total of 7,928 shares through two gift transactions. One transfer of 3,964 shares was made to a revocable trust that she controls under Rule 16a-13, shifting those shares from direct to indirect ownership. Following these transactions, she held 1,438 shares directly and 3,964 shares indirectly through the trust, indicating a reallocation of her holdings rather than an open-market sale.
Barg Steven reported acquisition or exercise transactions in this Form 4 filing.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Steven Barg reported an equity award of 1,438 shares of Common Stock on May 8, 2026. The award is a grant, not an open-market purchase, with a reference price of $177.62 per share.
Following this grant, Barg directly holds 2,865 shares. According to the footnote, the unvested restricted stock units underlying this award will vest on the earlier of May 8, 2027 or the business day before the company’s next annual shareholder meeting.
Thompson Craig B. reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International director Craig B. Thompson received a grant of 1,438 shares of Common Stock at $177.62 per share. This award is in the form of restricted stock units, increasing his directly held shares to 3,851.
The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.
Charles River Laboratories International director Paul W. Graves received a stock award as part of his compensation. On the reported date, he acquired 1,438 shares of common stock at a value of $177.62 per share through a grant, not an open-market purchase. Following this award, his directly held stake increased to 2,384 shares. The underlying restricted stock units will vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders.
Charles River Laboratories International, Inc. reported the results of its 2026 annual meeting of shareholders. Twelve directors were elected to serve until the 2027 annual meeting, each receiving more votes for than against, with broker non-votes recorded on each director proposal.
Shareholders approved, on an advisory, non-binding basis, the compensation of the company’s named executive officers and approved the new 2026 Long-Term Incentive Plan, which had previously been adopted by the board subject to shareholder approval. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2026.
Charles River Laboratories director Abraham Ceesay received a stock-based compensation award. On 5/8/2026, he acquired 1,438 shares of Common Stock at $177.62 per share as a grant or award, bringing his directly held stake to 2,384 shares. The related unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders, tying the award to continued service and future company performance rather than an open-market purchase.
MACKAY MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Martin Mackay received equity grants of common stock as part of his board compensation. He was awarded 1,407 shares at a reference price of $177.62 per share and a separate award of 1,438 shares at the same price. One award was granted in lieu of director service fees for the term beginning May 5, 2026. The restricted stock units vest on the earlier of May 8, 2027 or the business day before the company’s next annual meeting of shareholders. Following these awards, one reported line shows Mackay holding 17,137 shares directly.
Andrews Nancy C reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Nancy C. Andrews received an equity grant of 1,438 shares of Common Stock, valued at $177.62 per share. This was a compensation-related grant, not an open-market purchase, and increased her direct holdings to 5,402 shares.
The footnote states that the unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, tying the award to continued service and the company’s governance calendar.
Charles River Laboratories International director George Llado Sr. reported receiving equity-based compensation in the form of common stock awards. On May 8, 2026, he acquired 450 shares and a separate award of 1,438 shares, both at an indicated price of $177.62 per share.
Footnotes explain these are unvested restricted stock units that vest upon the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders. One grant was made in lieu of director service fees for the term commencing May 5, 2026.
Enyedy Mark J reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Mark J. Enyedy reported a stock award of 1,438 shares of Common Stock, valued at $177.62 per share. This was a compensation-related grant rather than an open-market purchase, bringing his direct holdings to 2,384 shares after the transaction.
The award consists of unvested restricted stock units that will vest upon the earlier of May 8, 2027, or the business day before the company’s next annual meeting of shareholders, aligning his compensation with long-term shareholder interests.